Evaluation of Axillary Lymph Node Marking with Magseed® before and after Neoadjuvant Systemic Therapy in Breast Cancer Patients: MAGNET Study

Table 1

Patient characteristics.

Characteristics	Overall (%)	Patients (Post-NAST) (%)	Patients (Pre-NAST) (%)
Number of patients (n)	81 (100)	37 (45.7)	44 (54.3)
Age
Mean (SD)	50.7 (12.7)	50.9 (10.9)	50.6 (14.1)
95% CI	(48.0; 53.5)	(47.4; 54.4)	(46.4; 54.7)
Median (min; max)	47.0 (29.0; 78.0)	47.0 (33.0; 78.0)	47.0 (29.0; 74.0)
P25; P75	41.0; 61.0	44.0; 56.0	40.0; 63.8
Initial tumor size (cm)
Mean (SD)	4.0 (2.9)	3.4 (2.1)	4.5 (3.4)
95% CI	(3.4; 4.7)	(2.8; 4.1)	(3.5; 5.6)
Median (min; max)	3.1 (0.0; 16.0)	2.8 (0.0; 9.1)	3.2 (1.5; 16.0)
P25; P75	2.3; 5.3	2.3; 3.6	2.6; 5.6
Initial lymph node staging
cN1	81 (100)	37 (100)	44 (100)
Tumor pathological response (Post-NAST)
Patients	79	36	43
pPR	45 (56.9)	18 (50.0)	27 (62.8)
pCR	34 (43)	18 (50.0)	16 (37.2)
Surgical procedure on the breast
Patients	81	37	43
BCS	51 (62.9)	26 (70.3)	25 (58.1)
MT	30 (37)	11 (29.7)	18 (41.9)
Molecular classification
Patients	81	37	44
HER + EP^+	27 (33.3%)	17 (45.9%)	10 (22.7%)
LB	41 (50.7%)	16 (43.3%)	25 (56.9%)
TN	10 (12.3%)	4 (10.8%)	6 (13.6%)
LA	2 (2.5%)	0 (0%)	2 (4.5%)
LB/HER2^+	1 (1.2%)	0 (0%)	1 (2.3%)

Information missing for 2 cases. BCS, breast-conserving surgery; EP, estrogen and progesterone receptor; HER2 human epidermal growth factor receptor; LA, luminal A; LB, luminal B; MT, mastectomy; NAST, neoadjuvant systemic therapy; pCR, pathological complete response; pPR, pathological partial response; TN, triple negative.